Literature DB >> 22659735

Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy.

Jorge S Burns1, Akmal Safwat, Giulia Grisendi, Moustapha Kassem, Massimo Dominici.   

Abstract

Mise en abyme meaning "placed into abyss or infinite recurrence" is an apt paradigm for the relentless growth of sarcoma cells. Its alternative meaning, "self-reflexive embedding" fits the central role attributed to cancer stem cells (CSCs). Diversely sourced and defined, mesenchymal stem cells (MSCs) may be the cells of sarcoma origin, evolve a CSC phenotype and/or contribute to tumor growth through inherent qualities for homing, neovascularization, paracrine cross-feeding, microvesicle secretion, cell fusion, entosis and immune modulation. Exploiting these qualities, MSC expressing modified forms of the TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) are being developed to complement more conventional radiation and chemotherapy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22659735     DOI: 10.1016/j.canlet.2012.05.027

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest.

Authors:  Jana Lützkendorf; Elisabeth Wieduwild; Katrin Nerger; Nina Lambrecht; Hans-Joachim Schmoll; Carsten Müller-Tidow; Lutz Peter Müller
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

Review 2.  Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells.

Authors:  Catharina Melzer; Juliane von der Ohe; Hendrik Lehnert; Hendrik Ungefroren; Ralf Hass
Journal:  Mol Cancer       Date:  2017-02-01       Impact factor: 27.401

3.  Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status.

Authors:  Pierre Avril; Louis-Romée Le Nail; Meadhbh Á Brennan; Philippe Rosset; Gonzague De Pinieux; Pierre Layrolle; Dominique Heymann; Pierre Perrot; Valérie Trichet
Journal:  J Bone Oncol       Date:  2015-12-12       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.